SBIR/STTR Research Award

Ultrasensitive detection of protein targets in plasma for early detection of cancer

Award identifier 4133a8113afbb27caa689d92098d11ffacb937596429e646682416c9558c052bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$321,869

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Alamar Biosciences, Inc.
Proposal award date
2020-07-01
Contract end date
2021-06-30
UEI
ED4RPQ2UJ9G8
Solicitation number
PA19-272
Topic code
102

Research abstract

PROJECT SUMMARY Early detection of cancer is amongst the most important problems to address in biomedical research because the earlier cancer is detected, the better chance of a cure or a successful treatment. In contrast to the current approach of DNA liquid biopsy, we propose to develop an ultra-sensitive immunoassay technology that enables protein liquid biopsy for early cancer detection. By leveraging our insights in improving signal-to-background ratio, we have developed a prototype immunoassay named NULISA, or NUcleic acid-Linked Immuno- Sandwich Assay, that has achieved unprecedented level of detection sensitivity of any commercially available immunoassays at ~20,000 molecules/mL (i.e. ~30 aM). In this proposal, we aim to optimize the NULISA assay to further boost lower limit of detection and limit of quantitation (LOD and LOQ) and test a few candidate markers for their potential in early cancer detection. The specific aims of this Phase 1 SBIR proposal include: 1) Optimize single plex NULISA for ultrasensitive detection of protein markers in plasma and demonstrate minimally 10- fold better detection sensitivity over the most sensitive immunoassay on market; and 2) Demonstrate initial proof of concept of NULISA for early cancer detection. At the end of this project, we expect to have established a high performance NULISA assay and the feasibility of novel markers for early cancer detection. The longer-term goal of the project is to develop noninvasive single- and/or pan-cancer screen tests that could detect cancer much earlier for more successful or curative treatment.PROJECT NARRATIVE This project aims to develop a novel ultra-sensitive immunoassay technology that enables protein liquid biopsy and demonstrates feasibility for early cancer detection. The longer-term goal of the project is to develop noninvasive single- and/or pan-cancer screen tests that could detect cancer much earlier for more successful or curative treatment.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.